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 Loss of glial cells with resulting atrophy of the medial prefrontal cortex 
(mPFC) as well as the hippocampal area is demonstrated in depressed 
patients by brain imaging and postmortem studies. The mPFC is the master 
control of mood and emotional response. The hippocampus is part of the 
limbic system, the main function of which is to regulate emotions. The 
mPFC depends on the hippocampus for rapid learning and memory 
consolidation. Unlike monoamine reuptake inhibitor antidepressants, which 
take 6 to 8 weeks to exert their full effects, and with 30-40% unresponsive 
rate, ketamine acts rapidly, within a couple of hours, and has higher 
responsive rates. It suggests that in theory, due to its rapid effect, Ketamine 
could well serve as a bridging remedy to lower the rate of suicidal risk before 
Selective serotonin re-uptake inhibitors (SSRIs) reach their full effect for 
long-term depression management. Yet, ketamine has long been linked with 
abusive potential and possible neurotoxicity if used in large doses over a 
prolonged period. Even though there are no collected data to prove the 
associated adverse effects, awareness of this negative aspect of ketamine is 
sufficiently widespread to propel the psychiatric community to look for other 
rapidly acting antidepressant alternatives. Recent studies have shown that 
scopolamine, the Yueju pill, and magnesium are rapid-onset antidepressants 
that have mechanisms comparable to that of ketamine. These rapid-acting 
antidepressant agents promise to be effective and safer choices for depression 
management in the future, providing for further studies and investigations to 
produce a better and fuller understanding of their effects and limitations. 
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1. INTRODUCTION 
Brain anatomical change and neurochemical shifts associated with depression have been observed in 
studies over the past 20 years [1-5]. The association between depression and neurobiology has led to further 
investigations focusing on the neuronal signaling pathways and neurotrophic factors, which can contribute to 
the morphological changes in the brain.  
Because the symptoms of depression can be improved by agents that act to increase synaptic 
concentrations of monoamines, antidepressant management in the past five decades has been focused on the 
monoamine hypothesis, which proposes that the underlying neurobiological basis for depression is a 
deficiency of noradrenergic and serotonergic systems, so that targeting of this neuronal lesion with a 
monoamine antidepressant could restore normal brain function [4]. In spite of that, less than one-third of 
major depression disorder (MDD) patients receiving standard antidepressants experienced remission after up 
to four months of treatment [6]. Typical SSRIs take six to eight weeks to alleviate depression symptoms. 
During this lag period, there is the risk of lapses in treatment, and of increasing suicidal ideation. 
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Undoubtedly, it is urgent and providers are obliged to develop faster acting and more effective 
antidepressants.  
Ketamine, an anesthetic medication, was first reported to have therapeutic effects in MDD in year 
2000 [7]. Ketamine, a rapid antidepressant, is N-Methyl-D-aspartate (NMDA)-receptor non competitive 
antagonist, and it upregulates brain-derived neurotrophic factor (BDNF) expression. BDNF is a member of 
the neurotrophin family of growth factors. Ketamine targets glutamate, the main excitatory amino acid 
neurotransmitter in the brain. Over-activation of the NMDA receptor by glutamate can lead to excitotoxicity, 
synaptic degradation, and neuron apoptosis. NMDA-receptor antagonists reduce glutamate binding and 
therefore decrease the excitotoxicity of neurons. One randomized controlled trial (RCT) of ketamine was 
conducted in treatment-resistant depression patients, including patients who had not responded to 
antidepressants with satisfactory therapeutic results [8]. Treatment-resistant depression refers to cases of 
MDD that do not respond satisfactorily to appropriate courses of at least two antidepressants [9]. Preclinical 
studies have indicated that repeated daily ketamine administration may have neurotoxic effects, particularly 
on the function of GABAergic interneurons [8]. The abusive potential and neurotoxicity possibility of 
ketamine warrant the search for alternative rapid-acting antidepressants. Scopolamine was found to reduce 
symptoms of depression within three days of the first administration [10-12]. The Yueju pill, an ancient 
Chinese herbal formula designed to treat mood disorders, is still popular today and found to be a rapid-onset 
antidepressant working through NMDA receptors and BDNF expression [13-15]. The level of magnesium, 
another NMDA-receptor antagonist, is found to be lower than normal in Treatment-resistant  
individuals [16-17]. 
These findings raise a number of questions. First, how might depression cause the atrophy of 
neurons, and under which signaling pathways, and neurotrophic factors? Second, how might ketamine 
reverse neuron damage and brain morphological changes? Third, how might scopolamine, the Yueju pill, and 
magnesium, produce a rapid antidepressant effect similar to that of ketamine?  
To clarify these concerns, we reviewed a large body of available clinical studies with patient data on 
ketamine antidepressant effects, studies of magnesium and scopolamine along with preclinical animal 
experiments of the Yueju pill. We discuss research that associates atrophy of the limbic system and the cortex 
with depression. We examine the effect of depression in terms of neurobiology and the promising novel rapid 
antidepressants. This article outlines the study background, important results, and the linkage of the 
underlying mechanisms of rapid-acting antidepressants. 
 
 
2. RESEARCH METHOD 
We used universal standards for qualitative research study when selecting articles and ensuring 
quality of the studies reviewed. The followings are criteria to include articles in the sample: (a) published in a 
peer- reviewed journal from 2000 to 2014; (b) cited in medical or related literature; (c) main focus on topic of 
rapid-acting antidepressants. Prospected articles were obtained by accessing PubMed database. Key words 
used included Treatment-resistant depression, ketamine, NMDA-receptor, glutamate, Yueju pill, and 
magnesium. Database searches combined yielded 50 articles for possible inclusion in the sample. Abstracts 
of articles were read to determine whether to obtain full texts of the studies. If the abstract of an article 
revealed the exclusive use of standardized data collection tools, and other quantitative measures, the article 
was not reviewed further. Articles that focused on rapid-acting antidepressants with qualitative methods were 
evaluated to be included in the sample. Based on the criteria for inclusion, the researchers selected 32 articles 
for the final sample. The focus of this paper was to analyze collective findings of qualitative studies on the 
broad topic of rapid-acting antidepressants. Each research study was carefully reviewed and summarized by 
the researchers according to this agenda, which included the following criteria: sample, research design, data 
analysis, and primary findings. 
 
 
3. RESULTS AND ANALYSIS 
3.1. Epidemiology of Depression 
Major depression disorder (MDD) is one of the most common prevalent lifetime mental disorders in 
the United States, affecting approximately 16.6% of the general population. According to the World Health 
Organization (WHO; 2010), major depression also carries the heaviest burden of disability among mental and 
behavioral disorders. Major depression is a mood disorder characterized by a sense of inadequacy, 
despondency, decreased activity, pessimism, anhedonia and sadness, where these symptoms severely disrupt 
and adversely affect the person's life. Further, depression is a life-threatening condition, preventing some 
patients from performing activities of daily living or causing self-destructive behavior, even suicide attempts.  
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3.2. Neurobiology of Depression 
Brain imaging studies of depressive patients reveal volume reduction in limbic brain regions: 
notably in the hippocampus and mPFC [1-2]. Post-mortem studies report a reduction of neurons and loss of 
glia. These studies confirm a well-established connection between loss of neurons and depression-related 
disorders. Neurotrophic factors play a major role in cell atrophy, and are supported by evidence that 
depression decreases certain neurotrophic factors in limbic brain regions. BDNF is one of the most studied 
neurotrophic factors. A reduction of BDNF in depressed subjects was revealed in post-mortem studies. This 
work suggested that BDNF is a significant biomarker of depression and treatment response [18-19]. On the 
other hand, antidepressant treatment elevates the expression of BDNF in the hippocampus and PFC [20]. 
Evidence also shows that antidepressant treatment is correlated with increases in BDNF in post-mortem 
brains of subjects on antidepressants at the time of death. Besides BDNF, there is evidence that links other 
neurotrophic/growth factors with depression, such as vascular endothelial growth factor (VEGF), fibroblast 
growth factor 2 (FGF-2), and insulin-like growth factor 1 (IGF-1). We further find depression and 
antidepressant treatments have contrasting effects on the expression of these factors. The “Neurotrophic 
hypothesis of depression and antidepressant response” proposes that depression results from decreased 
neurotrophic support, which causes neuronal atrophy, decreased hippocampal neurogenesis and loss of glia; 
antidepressant treatment reverses this deficit, and thereby reverses the brain atrophy and neuron loss [21]. 
Neuroplasticity is found to play a major role in mood disorders.  During depression progression, 
neurogenesis, neuron dendrites, and synaptogenesis are altered by stress and antidepressant treatments. 
Increasing activities of neurons cause the insertion of glutamate receptors and the formation of spine 
synapses [22]. 
 
3.3. Standard Antidepressants 
The typical antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), serotonin modulators (SMs), tricyclics (TCAs), and monoamine 
oxidase inhibitors (MAOIs). SSRIs are the newer agent and the most widely prescribed and standard 
antidepressants in the treatment of MDD. The reason for such antidepressants being the first-trial 
antidepressant treatment choice has mainly come from the monoamine hypothesis, which is based on 
practical experience, and improved tolerability compared with older antidepressants. However, close to one 
third of MDD patients failed to remit after undergoing standard SSRIs antidepressant treatment [6].  
 
3.4. Ketamine 
Before conventional antidepressant treatment becomes effective, usually over a period of one to two 
months, patients can discontinue the medication, resulting in increased suicidal risk [23-25]. As a result, the 
discovery of treatments with a more rapid onset action became a major goal of biological psychiatry. The 
first drug found to produce rapid improvement in mood was the NMDA glutamate receptor antagonist, 
ketamine that demonstrates rapid and effective symptom relief in treatment-resistant patients with major 
depression. Recent clinical and animal studies reveal that a subanesthetic dose of ketamine can rapidly 
alleviate depressive symptoms, and its effect can last a few days to a week long [26]. Experimental studies 
also suggest that the rapid enhancement of BDNF expression and synaptic plasticity in given brain regions 
are responsible for this effect [27].  
One study suggests that ketamine-induced antidepressant effects are associated with  
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors-mediated upregulation of the 
mammalian target of rapamycin complex 1 (mTORC1) and BDNF in the rat hippocampus and prefrontal 
cortex [20]. The NMDA-receptor is pre-synaptic, while the AMPA-receptor is post-synaptic. mTORC1 is a 
key transcription agent that amplifies the frequency of excitatory postsynaptic currents, and extracellular 
glutamate in the mPFC. Another report suggests that ketamine deactivates the eukaryotic elongation factor  
2 (eEF2) kinase, leading to reduced eEF2 phosphorylation and therefore an increasing translation of BDNF. 
Furthermore, a single dose of ketamine induced a rapid and complete reversal of spine deficit and function 
caused by three weeks of chronic, unpredictable stress exposure [21]. Based on case studies, open-label 
surveys, and controlled trials up to date, Ketamine can be a novel option with less adverse effects for 
treatment-resistant depression patients who have tried and failed two or more antidepressant medications, and 
electroconvulsive therapy (ECT) [9]. There are also reports that ketamine is effective for treatment of suicidal  
emergency [23-25]. However, lack of long-term follow up data and its potential for abusive use have 
restricted the provision of ketamine infusions to clinics and hospital settings, where they can be administered 
under the supervision of medical professionals.   
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Figure 1. Edited Picture from Duman et al 2012 [28] 
 
 
3.5. Scopolamine 
Clinical studies report that scopolamine, a muscarinic receptor antagonist used for motion sickness, 
produces rapid antidepressant effects in depressed patients [10]. Similar to ketamine, scopolamine increased 
signaling by mTORC1, which is connected to the rapid actions of NMDA-receptor antagonists [11-12]. The 
results confirm that the antidepressant actions of scopolamine involve mTORC1 signaling, increased 
glutamate transmission, and synaptogenesis, thus acting in a manner similar to NMDA-receptor antagonists. 
One randomized, double-blind, placebo-controlled RCT investigation examined the efficacy and safety of 
scopolamine in moderate-to-severe MDD, and the augmentation with scopolamine was significantly more 
effective than the placebo [10]. Patients receiving scopolamine showed higher rates of response (65%) and 
remission (65%) than the placebo group (30%). Scopolamine blocks the muscarinic receptor, which is 
thought to be overactive in patients with MDD.  
The efficacy of scopolamine through the blockade of muscarinic receptors is also the same 
mechanism as that of tricyclic antidepressant medications (TCAs), the oldest type of antidepressants. With 
TCAs, the muscarinic receptor blockade was viewed as the cause of undesired cholinergic side effects. For 
that reason, the newer antidepressants, such as SSRIs or SNRIs, were specially designed to avoid the 
muscarinic-receptor antagonist effect. It is, however, a common consequence for patients treated with 
scopolamine to present with higher rates of dry mouth, blurred vision, and dizziness. 
 
3.6. The Yueju Pill 
“Yueju” means “escaping depression” in Chinese. It was formulated 800 years ago by a famous 
Chinese doctor, Danxi Zhu. It is still popularly prescribed today to treat depression and loss of appetite. 
Yueju is composed of five equal amount of herbs, Xiang Fu, Chuan Xiong, Zhi zi, Cang Zu, and Shen Qu. 
Animal preclinical studies have shown that Yueju is an effective antidepressant [13-15]. It has been 
previously reported that ethanol extract of Yueju has antidepressant effect after a week-long  
administration [15]. In addition, only a single Yueju ethanol extract administration is needed to demonstrate a 
rapid antidepressant effect in the Learned Helpless Paradigm. It significantly reduced the number of escape 
failures. The latency to escape also showed a trend to decrease in Yueju-treated mice [13]. Many active 
components in Yueju are essential oils that may be extracted with ethanol, such as α-cyperone and β-
cyperone in Xiang Fu and atractylin and hinesol in Cang Zhu [15], [29]. The effective components of Yueju 
regulate glutamate in a way similar to ketamine, and require further investigation. 
Yueju, similar to ketamine, rapidly increased the expression of BDNF in the hippocampus, whereas 
the BDNF mRNA expression remained unaltered [13]. This is likely to have resulted from posttranscriptional 
regulation. Yueju rapidly reduced the phosphorylation of eEF2 in the hippocampus, leading to the 
desuppression of BDNF synthesis. BDNF protein expression was rapidly increased by Yueju, and 
antidepressant-like effects of Yueju were sustained for 24 hours in mice, but decreased after 24 hours. In 
contrast, eEF2 was continuously dephosphorylated in ketamine-treated mice at 24 hours [13]. Yueju, as an 
herbal medicine, is found to be effective and lasting as a rapid antidepressant comparable to ketamine. The 
fast induction of BDNF may be the underlying mechanism responsible for the rapid antidepressant action of 
ketamine and Yueju. This discovery opens a new path to seek better alternative management for MDD. 
However, the dosage amount used in (Xue W, et al, 2013) is much higher than the recommended prescription 
used in depressed patients.  
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3.7. Magnesium 
Magnesium Deficiency can subject patients to neuropathology. Magnesium ions regulate calcium 
ion flow in calcium channels. Calcium and glutamate are both excitatory, and in excess, neurotoxic. Calcium 
activates the NMDA receptor. Magnesium deactivates NMDA receptors, of which the main functions are 
synaptic plasticity control and memory formation. In magnesium deficiency, neuronal damage from overly 
activated neuronal receptors could manifest as depression [16], [30]. These magnesium ion neuronal deficits 
may be induced by stress hormones, dietary deficiencies of magnesium as well as excessive dietary calcium. 
Refined flour contains only 16% of the magnesium found in whole wheat. Excessive alcohol drinking can 
also deplete magnesium storage in the body. Case studies showed rapid recovery, less than 7 days, from 
MDD using 125-300 mg of magnesium four times a day [17]. The possibility that magnesium deficiency is 
the cause of most MDD is of enormous importance to public health, in that it affects the population at large, 
and is therefore recommended for further and advanced research. Nonetheless, magnesium deficiency of can 
be ameliorated easily by the consumption of whole grains and/or nutritional supplements. This simple 
implementation can prevent or at least lower the incidence of MDD and the undesirable outcomes associated 
with it. 
 
 
4. DISCUSSION 
Current conventional antidepressants act slowly, and it is urgent to develop the therapeutics that can 
quickly and enduringly treat depression. In an effort to elucidate the mechanisms of rapid-acting 
antidepressants implicated in treating major depression disorder, we conducted a thorough literature review 
on the most recent research related to fast-onset antidepressants and their related mechanisms.  
The reason that depression causes cortical atrophy can be answered best with the theory known as 
“Neurotrophic hypothesis of depression”, which states that depression results from decreased neurotrophic 
support, which causes neuronal atrophy, decreased hippocampal neurogenesis and loss of glia. Reduction of 
BDNF is also found in depressed subjects.  
Ketamine reverse neuron damage by deactivating eEF2 kinase, and increasing the translation of 
BDNF, which regulates neuronal survival and differentiation. Consequently, ketamine stops the 
morphological changes of the brain due to depression.  
The possible reason that ketamine acts fast globally is that it works against glutamate, the main 
excitatory neurotransmitter present in more than 50% of nervous tissue. Traditional antidepressants act 
through monoamines, such as serotonin and dopamine, which are only present in 15% of nervous tissue. It is 
exciting to discover the mechanism of novel rapid-acting antidepressants such as ketamine, scopolamine, the 
Yueju pill, and magnesium and their relationship with glutamate.  
It is understood that the deficits in different forms of neuroplasticity, including synaptic mechanism 
and neurotrophic mechanism, are responsible for depression [19], [31]. BDNF is the best studied 
neurotrophic factor concerned in depression. Increasing numbers of studies support the view that BDNF is 
necessary for mediating antidepressant effects [18]. Typical monoamine antidepressants increase BDNF only 
after long-term administration [5]. After being carefully studied and examined, the mechanisms of the 
recently discovered rapid-acting antidepressants, the linkage and interactions between glutamate, mTORC1 
signaling, BDNF, and synaptogenesis are the key to understanding depression. Further research focused on 
these areas will help to develop safer and more effective rapid-acting antidepressant agents.  
To our knowledge, this is the first and only study that reports the connection between different 
rapid-acting antidepressants and the mechanisms behind their actions. Decreasing glutamate transmission 
allows neurons to rest and gives them the opportunity to regenerate. Enhancing BDNF expression indicates 
upregulation of neuroplasticity, which is found in many studies to alleviate depression symptoms. Sufficient 
evidence supports the function of BDNF in the survival and differentiation of neurons. BDNF employs acute 
effects on the transmission and plasticity of synapses, and heightens excitatory synaptic transmission. Our 
recent studies have revealed a novel cooperative interaction between BDNF and glutamate in the regulation 
of dendritic development. These studies draw attention to the significance of the collaboration between 
BDNF and glutamate in the regulation of synaptic transmission and neuronal development.   
 
 
5. CONCLUSION 
The present studies advocate the association of depression with glutamate and BDNF in ketamine, 
scopolamine, the Yueju pill, and magnesium for future antidepressant development. Clarifying the 
relationship of glutamate, BDNF and the signaling pathways might help to understand the exact contribution 
of neuroplasticity and permit diagnostic and therapeutic advances in depression management. Although these 
findings pave the way to a theoretically different approach to the treatment of depression, it awaits additional 
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studies for rapid-acting antidepressants to become clinically practicable. This possibility needs to be 
established empirically in studies to demonstrate rapid-acting antidepressant treatments can be implemented 
with less adverse effects, transitioned to long-term treatment, and management for major depression disorder. 
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